Clinical trial NCT00319930: Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Official title: A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(Allylamino)-17-demethoxy-geldanamycin [17-AAG]) in Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Chronic Lymphocytic Leukemia
Keywords: Chronic lymphocytic leukemia
CLL
ZAP-70
Hsp90 inhibitor
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2006-04-27
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.


Eligibility criteria: Key Inclusion Criteria:

1. Diagnosis of B-cell CLL including

   * Lymphocytosis of \>=5,000 monoclonal B-cells/microliter co-expressing \>= one B-cell marker (CD19, CD20, or CD23) and CD5 in peripheral blood AND
   * \<= 55% prolymphocytes AND
   * Bone marrow with \>=30% mononuclear cells being lymphocytes
2. ZAP-70 positive CLL
3. Intermediate or High risk, poor prognosis CLL refractory to fludarabine-based therapy as defined by one of the following:

   * Disease progression following 2 cycles of fludarabine OR
   * Failure to achieve PR or CR after at least 2 cycles OR
   * No response to treatment or stable disease after at least 2 cycles of fludarabine OR
   * Disease progression after chemotherapy treatment after fludarabine-based therapy

   OR

   · CLL patients intolerant to fludarabine-based therapy. \[Intolerance is defined as the development of any serious medical condition occurring after exposure to fludarabine that would restrict further use of the agent as treatment for the patient's CLL (i.e., autoimmune hemolytic anemia, myelosuppression, hypersensitivity)\]
4. Indication for treatment as defined by the NCI Working Group Guidelines
5. Laboratory parameters as follows:

   * Hemoglobin \>=10 g/dL (may be post-transfusion); platelet count \>=50 x103/mm3
   * T. Bili \<2 x ULN and ALT and AST \<2 x ULN
   * Creatinine \<=2 x ULN
6. ECOG Performance Score \<=2
7. For patients of child-producing potential, use of effective contraceptive methods during the study and for 1 month following treatment

Key Exclusion Criteria:

1. Pregnant or nursing women
2. Class III or IV cardiac disease defined by the New York Heart Association Functional Classification and/or left ventricular ejection fraction \<40%
3. History of prior radiation that potentially included the heart in the field.
4. History of myocardial infarction or active ischemic heart disease within 6 months of study entry
5. History of arrhythmia (including atrial fibrillation, multifocal premature ventricular contractions, ventricular bigeminy or trigeminy, ventricular tachycardia or a requirement for antiarrhythmics (including digoxin)
6. Baseline QTc \>=450 msec for men and \>= 470 msec for women in the absence of correctable electrolyte imbalance
7. Poorly controlled angina
8. Congenital long QT syndrome or first-degree relative with unexplained sudden death \<40 years of age
9. Presence of left bundle branch block
10. Treatment with chemotherapy, monoclonal antibody or radiotherapy within 28 days of study entry
11. Severe or debilitating pulmonary disease
12. Participation in any investigational drug study within 28 days prior to CNF1010 administration. (Patient must have recovered from all acute effects of previously administered investigational agents)
13. Presence of active malignancy with the exception of basal cell carcinoma
14. Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral (A, B or C) hepatitis
15. Known allergy to soy
16. Requirement for concomitant therapy with drugs that alter metabolism by cytochrome P450 3A4 except low-dose warfarin for implanted device patency
17. Requirement for concomitant therapy with drugs that prolong or may prolong QTc interval

Primary outcomes:
measure: The minimal biologically active dose (MBAD)
measure: Safety and toxicity profile
measure: Pharmacokinetics (PK)
measure: Pharmacodynamics (PD)
measure: Clinical and hematological response
Secondary outcomes:
Other outcomes:
Locations:
city: Ocoee
country: United States
state: Florida
city: Albany
country: United States
state: New York
city: Dayton
country: United States
state: Ohio
city: Greenville
country: United States
state: South Carolina
city: Tyler
country: United States
state: Texas
city: Norfolk
country: United States
state: Virginia
Study officials:
References: